Birinapant showed consistent on-target suppression of cIAP1 in tumor biopsies and peripheral blood mononuclear cells, but single-agent anti-tumor activity did not meet the pre-specified primary endpoint of 20% response rate in order to justify proceeding with the development of the single agent [10]. Here, BIRC2 is linked to neoplasm.